Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07149649 | Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) | recruiting | Phase 2 / Phase 3 | 230 | Swiss Cancer InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07306624 | Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer | recruiting | Phase 2 | 62 | STCube, Inc.INDUSTRY | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07708870 |
| Nurse-Led Caregiver Support for Older Adults With Advanced Lung Cancer(ICSM) |
| recruiting |
| N/A |
| 120 |
| National Taiwan University HospitalOTHER |
| 1 |
| Jul 16, 2026 |
| clinicaltrials |
| NCT07709585 | Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients(BE-MASTER) | not yet recruiting | Phase 2 | 124 | Guangzhou University of Traditional Chinese MedicineOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03456076 | A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer | active not recruiting | Phase 3 | 257 | Hoffmann-La RocheINDUSTRY | 27 | Jul 15, 2026 | clinicaltrials |
| NCT03819296 | Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer | recruiting | Phase 1 | 800 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT04407247 | Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma | active not recruiting | Phase 1 / Phase 2 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT04922658 | Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 76 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT05800015 | A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer | active not recruiting | Phase 2 / Phase 3 | 160 | Regeneron PharmaceuticalsINDUSTRY | 10 | Jul 15, 2026 | clinicaltrials |
| NCT07405190 | Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC | recruiting | Phase 2 | 46 | Massachusetts General HospitalOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07653438 | In Vivo Fluorescence Molecular Bronchoscopy of Durvalumab-680LT in Patients With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) After Chemoradiotherapy(PulmoPrint) | not yet recruiting | Phase 2 | 20 | University Medical Center GroningenOTHER | 0 | Jul 15, 2026 | clinicaltrials |
| NCT07704645 | The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 180 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 15, 2026 | clinicaltrials |
| NCT01505400 | Integrated Molecular Profiling in Advanced Cancers Trial(IMPACT) | active not recruiting | — | 3,026 | University Health Network, TorontoOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT04995523 | A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC(ARTEMIDE-01) | active not recruiting | Phase 1 / Phase 2 | 212 | AstraZenecaINDUSTRY | 16 | Jul 14, 2026 | clinicaltrials |
| NCT06577792 | Lobectomy-First vs. Lymphadenectomy-First for Operable NSCLC (LOFTY)(LOFTY) | active not recruiting | N/A | 620 | Sun Yat-sen UniversityOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06686771 | Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer(CURB2) | recruiting | Phase 3 | 320 | Canadian Cancer Trials GroupNETWORK | 2 | Jul 14, 2026 | clinicaltrials |
| NCT07416474 | RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC) | recruiting | Phase 3 | 574 | RemeGen Co., Ltd.INDUSTRY | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07613424 | A Study of MET Concordance and Gene Profiling in 1L NSCLC (Genomet)(Genomet) | recruiting | N/A | 1,000 | AstraZenecaINDUSTRY | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07669779 | A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer | recruiting | Phase 2 | 348 | AkesoINDUSTRY | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07689643 | Safety and Preliminary Efficacy of [177Lu]Lu-RTX-2358 Combined With Immune Checkpoint Inhibitors in Patients With FAP-positive Metastatic Non-Small Cell Lung Cancer | recruiting | Early Phase 1 | 36 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07699757 | HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion | not yet recruiting | Phase 1 | 258 | Haisco Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07703228 | Second-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced Driver Gene-Negative Non-Squamous NSCLC | active not recruiting | Phase 2 | 38 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05628376 | TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO | recruiting | — | 600 | University College, LondonOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05787587 | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors | active not recruiting | Phase 1 | 216 | IDEAYA BiosciencesINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07535437 | A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 66 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07697716 | In Vitro NSCLC EGFR-Mutant Models for Drug Sensitivity Testing(PRECISE-EGFR) | not yet recruiting | — | 30 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 0 | Jul 13, 2026 | clinicaltrials |
| NCT07699328 | A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer(REACH-EGFR) | recruiting | Phase 1 / Phase 2 | 315 | Voronoi, IncINDUSTRY | 10 | Jul 13, 2026 | clinicaltrials |
| NCT05048797 | A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations | active not recruiting | Phase 3 | 454 | AstraZenecaINDUSTRY | 20 | Jul 10, 2026 | clinicaltrials |
| NCT05985330 | Pilot Study of the Contribution of Fractional Exhaled Nitric Oxide as a Prognostic Marker of Response to Anti-PD-L1 Immunotherapy in Non-small Cell Lung Cancer(FENOTYPE) | recruiting | — | 56 | Centre Hospitalier Universitaire DijonOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06670196 | A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | active not recruiting | Phase 3 | 420 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06695845 | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | recruiting | Phase 2 | 200 | Jazz PharmaceuticalsINDUSTRY | 3 | Jul 10, 2026 | clinicaltrials |
| NCT07355205 | First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer(FLINN) | recruiting | Phase 1 / Phase 2 | 26 | Washington University School of MedicineOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07452224 | ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer | recruiting | Phase 2 | 80 | iLeukon Therapeutics, Inc.INDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05937906 | Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %.(IMMUNOMEK) | recruiting | Phase 1 / Phase 2 | 24 | Centre Georges Francois LeclercOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT04328844 | A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers | active not recruiting | Phase 1 | 210 | iOncturaINDUSTRY | 2 | Jul 8, 2026 | clinicaltrials |
| NCT05003037 | Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 106 | Li Zhang, MDOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT05543330 | A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC | recruiting | Phase 1 / Phase 2 | 116 | Wuhan YZY Biopharma Co., Ltd.INDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06103682 | LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)(OBLITERATE) | recruiting | N/A | 100 | University of California, DavisOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06139627 | Evaluation of Geriatric Assessment and Management for Older Adults With Non-small Cell Lung Cancer Receiving Chemotherapy Radiation Therapy | recruiting | N/A | 180 | City of Hope Medical CenterOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06711900 | A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | active not recruiting | Phase 3 | 432 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06939595 | A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer | active not recruiting | Phase 3 | 225 | CelltrionINDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07314216 | Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma | recruiting | Phase 2 | 15 | Hunan Cancer HospitalOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07689721 | ctDNA-Guided Intraventricular Therapy for CNS Malignancies(GUIDE-CNS) | not yet recruiting | N/A | 77 | Alireza MansouriOTHER | 0 | Jul 8, 2026 | clinicaltrials |
| NCT04765059 | A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)(COMPEL) | active not recruiting | Phase 3 | 98 | AstraZenecaINDUSTRY | 6 | Jul 7, 2026 | clinicaltrials |
| NCT04906746 | Ruxolitinib for Cancer Cachexia | active not recruiting | Early Phase 1 | 10 | Tu DanOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT05424029 | Extracellular Vesicles and Particles (EVP) as Biomarkers of Recurrence in Non-Small Cell Lung Cancer | recruiting | — | 200 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06268210 | Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(NeoLazer) | active not recruiting | Phase 2 | 160 | Yonsei UniversityOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06348199 | A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer | active not recruiting | Phase 3 | 555 | Samsung Bioepis Co., Ltd.INDUSTRY | 14 | Jul 7, 2026 | clinicaltrials |
| NCT06552234 | Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC(REPOROS) | recruiting | Phase 2 | 30 | Centre Hospitalier Intercommunal de Toulon La Seyne sur MerOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06699979 | Multi-omics Study of Early-stage Lung Cancer With Distinct Phenotypes | recruiting | — | 300 | Central South UniversityOTHER | 1 | Jul 7, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jul 16, 2026source: clinicaltrials